Bourgeois Pierre
Service of Nuclear Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.
J Nucl Med. 2007 May;48(5):693-5. doi: 10.2967/jnumed.107.039594.
Volumes injected for lymphoscintigraphic investigations are highly variable, and the quantity of labeled colloids injected is usually not reported. The aim of the present study was to evaluate whether and how volume and quantity quantitatively affect lymphoscintigraphic results.
Each of 9 healthy volunteers (4 men and 5 women; mean age, 21 y; range, 19-26 y) participated in 4 lymphoscintigraphic investigations using the same protocol, in which the volume injected was 0.2 or 1.0 mL and the quantity injected was 0.02 or 0.2 mg. Subcutaneous injections of (99m)Tc-labeled human serum albumin nanosized colloids were placed in the first interdigital space of each foot. Activity at the injection sites and in the inguinoiliac nodes after a standardized sequence of rest, exercise, and normal-activity periods was measured and analyzed as a function of volume and quantity.
The highest extraction rate was observed for a quantity of 0.2 mg and a volume of 0.2 mL. This extraction rate was significantly higher than the rates obtained for a quantity of 0.2 mg and a volume of 1.0 mL or for a quantity of 0.02 mg and a volume of 0.2 mL, neither of which differed from the extraction rate for a quantity of 0.02 mg and a volume of 1.0 mL. Activity in inguinoiliac nodes was significantly higher for a quantity of 0.2 mg than for a quantity of 0.02 mg, irrespective of volume. With quantity remaining constant, volume did not influence the activity in inguinoiliac nodes.
Both volume and quantity influence the results of lymphoscintigraphic investigations with regard to the quantities extracted from injection sites and the accumulations in nodal regions. Therefore, volume and quantity should be standardized when quantitative parameters are used for diagnostic purposes.
用于淋巴闪烁显像检查的注射体积差异很大,且通常未报告注射的标记胶体的量。本研究的目的是评估体积和量是否以及如何定量影响淋巴闪烁显像结果。
9名健康志愿者(4名男性和5名女性;平均年龄21岁;范围19 - 26岁)中的每一位都按照相同方案参与了4次淋巴闪烁显像检查,其中注射体积为0.2或1.0 mL,注射量为0.02或0.2 mg。将(99m)Tc标记的人血清白蛋白纳米胶体皮下注射到每只脚的第一趾蹼间隙。在标准化的休息、运动和正常活动时间段序列后,测量并分析注射部位和腹股沟淋巴结的活性,将其作为体积和量的函数。
观察到量为0.2 mg且体积为0.2 mL时提取率最高。该提取率显著高于量为0.2 mg且体积为1.0 mL或量为0.02 mg且体积为0.2 mL时获得的提取率,这两种情况的提取率与量为0.02 mg且体积为1.0 mL时的提取率均无差异。无论体积如何,腹股沟淋巴结中的活性在量为0.2 mg时显著高于量为0.02 mg时。在量保持不变的情况下,体积不影响腹股沟淋巴结中的活性。
体积和量在从注射部位提取的量以及淋巴结区域的积聚方面均影响淋巴闪烁显像检查的结果。因此,当将定量参数用于诊断目的时,体积和量应标准化。